Skip to main content

Table 1 Patient characteristics

From: Prognostic value of radiological findings indeterminate for UIP pattern and anterior upper lobe honeycomb-like lesion in chronic fibrosing interstitial lung disease associated with MPO-ANCA

 

All subjects (n = 61)

MPA-ILD (n = 22)

Non-MPA-ILD (n = 39)

P value

Age, mean ± SD

75.1 ± 8.8

75.1 ± 9.2

75.2 ± 8.2

0.973

Male, N (%)

31 (50.8%)

9 (40.9%)

22 (56.4%)

0.293

Current or ex-smoker, N (%)

35 (57.4%)

11 (50.0%)

24 (61.5%)

0.428

BMI, kg/m2, mean ± SD

22.1 ± 3.1

23.2 ± 3.3

21.5 ± 2.9

0.037

Acute exacerbation of ILD, N (%)

9 (14.8%)

1 (4.5%)

8 (20.5%)

0.138

Diffuse pulmonary hemorrhage, N (%)

6 (9.8%)

6 (27.3%)

0 (0.0%)

 < 0.001

KL-6 (U/mL), mean ± SD (available N = 56)

913.9 ± 824.4

726.2 ± 594.3

1010.3 ± 913.0

0.225

SP-D (ng/mL), mean ± SD (available N = 40)

151.9 ± 116.8

91.9 ± 76.8

169.3 ± 121.5

0.080

CRP (mg/dL), mean ± SD (available N = 61)

1.8 ± 2.7

1.6 ± 2.5

2.1 ± 3.0

0.475

%FVC, mean ± SD (available N = 31)

91.2 ± 19.1

98.3 ± 12.5

87.9 ± 21.0

0.160

FEV1/FVC ratio, % mean ± SD (available N = 31)

77.3 ± 9.4

78.8 ± 9.8

76.5 ± 9.4

0.540

%DLCO, mean ± SD (available N = 29)

81.5 ± 22.0

84.6 ± 15.5

79.9 ± 24.9

0.594

CPI, mean ± SD (available N = 29)

27.7 ± 18.3

24.1 ± 13.1

29.6 ± 20.5

0.445

Anti-inflammatory agent (during follow-up), N (%)

35 (57.4%)

21 (95.5%)

14 (35.9%)

 < 0.001

Anti-fibrotic agent (during follow-up), N (%)

4 (6.6%)

0 (0.0%)

4 (10.3%)

0.287

Deaths (during follow-up), N (%)

25 (41.0%)

9 (40.9%)

16 (41.0%)

 > 0.999

Median follow-up, years (range)

3.6 (0.1–11.9)

3.2 (0.1–11.9)

3.8 (0.2–11.7)

0.376

  1. BMI body mass index, CPI  composite physiological index, CRP C-reactive protein, DLCO diffusing capacity of the lung for carbon monoxide, FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, ILD interstitial lung disease, KL-6 Krebs von den Lungen-6, MPA microscopic polyangiitis, SP-D surfactant protein-D